Form 4: Opus Genetics SVP Hoffmann Receives Stock and Option Grants

Bernhard Hoffmann, SVP of Corporate Development at Opus Genetics, was granted 29,500 shares of common stock and an option to purchase 29,500 shares on March 13, 2025.

Summary

• Bernhard Hoffmann, SVP of Corporate Development at Opus Genetics, received a grant of 29,500 shares of common stock on March 13, 2025.
• These shares are restricted stock units that will vest in four equal installments annually, starting on March 13, 2026, contingent upon Hoffmann's continued service.
• Hoffmann also received an option to purchase 29,500 shares of common stock at an exercise price of $0.93.
• The option vests with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly over the following 12 quarters, also subject to continued service.
• Following these transactions, Hoffmann beneficially owns 185,446 shares of Opus Genetics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock and options indicates confidence in the executive and the company's future, but it's a routine event.

Positives

• The grant of stock and options to a key executive like the SVP of Corporate Development suggests the company is incentivizing leadership to drive future growth.
• The vesting schedules for both the stock and options are tied to continued service, aligning the executive's interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Stock and option grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. These grants align the executive's interests with those of the shareholders by rewarding long-term value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation tools in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options and RSUs extensively in their executive compensation packages.
• The vesting schedules described are typical, with vesting periods of 3-4 years being common to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the grants positively as aligning management's interests with long-term value creation.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates